Imatinib mesylate in the treatment of chronic myelogenous leukemia : Current therapeutic approach for chronic myeloid/Myeloproliferative disorder: Focus on imatinib mesylateBORTHAKUR, Gautam; CORTES, Jorge E.International journal of hematology. 2004, Vol 79, Num 5, pp 411-419, issn 0925-5710, 9 p.Article

Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous LeukemiaGANDHI, Varsha; PLUNKETT, William; CORTES, Jorge E et al.Clinical cancer research (Print). 2014, Vol 20, Num 7, pp 1735-1740, issn 1078-0432, 6 p.Article

Molecular Monitoring in Chronic Myeloid Leukemia : Response to Tyrosine Kinase Inhibitors and Prognostic ImplicationsJABBOUR, Elias; CORTES, Jorge E; KANTARJIAN, Hagop M et al.Cancer. 2008, Vol 112, Num 10, pp 2112-2118, issn 0008-543X, 7 p.Article

Biology of platelet-derived growth factor and its involvement in diseaseALVAREZ, Ricardo H; KANTARJIAN, Hagop M; CORTES, Jorge E et al.Mayo Clinic proceedings. 2006, Vol 81, Num 9, pp 1241-1257, issn 0025-6196, 17 p.Article

The role of Src in solid and hematologic malignancies : Development of new-generation Src inhibitorsALVAREZ, Ricardo H; KANTARJIAN, Hagop M; CORTES, Jorge E et al.Cancer. 2006, Vol 107, Num 8, pp 1918-1929, issn 0008-543X, 12 p.Article

Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicinYUK FUNG HUI; CORTES, Jorge E.Pharmacotherapy. 2000, Vol 20, Num 10, pp 1221-1223, issn 0277-0008Conference Paper

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Recall following different chemotherapy agentsYUK FUNG HUI; GILES, Francis J; CORTES, Jorge E et al.Investigational new drugs. 2002, Vol 20, Num 1, pp 49-53, issn 0167-6997, 5 p.Article

Early Cytogenetic and Molecular Response During First-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase: Long-Term ImplicationsQUINTAS-CARDAMA, Alfonso; CORTES, Jorgé E; KANTARJIAN, Hagop M et al.Cancer. 2011, Vol 117, Num 23, pp 5261-5270, issn 0008-543X, 10 p.Article

Current and emerging treatment options in chronic myeloid leukemiaJABBOUR, Elias; CORTES, Jorge E; GILES, Francis J et al.Cancer. 2007, Vol 109, Num 11, pp 2171-2181, issn 0008-543X, 11 p.Article

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemiaCHEN, Lisa S; REDKAR, Sanjeev; TAVERNA, Pietro et al.Blood. 2011, Vol 118, Num 3, pp 693-702, issn 0006-4971, 10 p.Article

Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid LeukemiaJABBOUR, Elias; BRANFORD, Susan; SAGLIO, Giuseppe et al.Cancer. 2011, Vol 117, Num 9, pp 1800-1811, issn 0008-543X, 12 p.Article

Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML TherapyKANTARJIAN, Hagop M; BACCARANI, Michele; JABBOUR, Elias et al.Clinical cancer research (Print). 2011, Vol 17, Num 7, pp 1674-1683, issn 1078-0432, 10 p.Article

Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain MutationsALVARADO, Yesid; KANTARJIAN, Hagop M; LUTHRA, Rajyalakshmi et al.Cancer. 2014, Vol 120, Num 14, pp 2142-2149, issn 0008-543X, 8 p.Article

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication StatusCORTES, Jorge E; KANTARJIAN, Hagop; LEVIS, Mark et al.Journal of clinical oncology. 2013, Vol 31, Num 29, pp 3681-3687, issn 0732-183X, 7 p.Article

Daily Palonosetron Is Superior to Ondansetron in the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Acute Myelogenous LeukemiaMATTIUZZI, Gloria N; CORTES, Jorge E; BLAMBLE, Deborah A et al.Cancer. 2010, Vol 116, Num 24, pp 5659-5666, issn 0008-543X, 8 p.Article

Dasatinib Early Intervention After Cytogenetic or Hematologic Resistance to Imatinib in Patients With Chronic Myeloid LeukemiaQUINTAS-CARDAMA, Alfonso; CORTES, Jorge E; O'BRIEN, Susan et al.Cancer. 2009, Vol 115, Num 13, pp 2912-2921, issn 0008-543X, 10 p.Article

Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib ResistanceZHANG, Wenyong W; CORTES, Jorge E; HUI YAO et al.Journal of clinical oncology. 2009, Vol 27, Num 22, pp 3642-3649, issn 0732-183X, 8 p.Article

Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor LeukemiaBORTHAKUR, Gautam; LIN, E; JAIN, Nitin et al.Cancer. 2009, Vol 115, Num 14, pp 3217-3221, issn 0008-543X, 5 p.Article

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosomeEL-ZIMAITY, Maha M. T; KANTARJIAN, Hagop; NEBIYOU BEKELE, B et al.British journal of haematology. 2004, Vol 125, Num 2, pp 187-195, issn 0007-1048, 9 p.Article

Adaptive randomized study of idarubicin and cytarabine versus Troxacitabine and cytarabine versus Troxacitabine and idarubicin in untreated Patients 50 years or older with adverse karyotype acute myeloid leukemiaGILES, Francis J; KANTARJIAN, Hagop M; XIAO, Lian-Chun et al.Journal of clinical oncology. 2003, Vol 21, Num 9, pp 1722-1727, issn 0732-183X, 6 p.Article

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesKANTARJIAN, Hagop M; CORTES, Jorge E; BOCHINSKI, Kathy et al.Blood. 2003, Vol 101, Num 1, pp 97-100, issn 0006-4971, 4 p.Article

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemiaGILES, Francis J; GUANGPING SHI, Gary; CORTES, Jorge E et al.Cancer chemotherapy and pharmacology. 2003, Vol 52, Num 3, pp 223-228, issn 0344-5704, 6 p.Article

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemiaOSTRONOFF, Fabiana; OTHUS, Megan; PETERSDORF, Stephen H et al.British journal of haematology. 2013, Vol 163, Num 1, pp 130-132, issn 0007-1048, 3 p.Article

Epoetin Alpha Decreases the Number of Erythrocyte Transfusions in Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, and Burkitt Leukemia/Lymphoma: Results of a Randomized Clinical TrialCABANILLAS, Maria E; KANTARJIAN, Hagop; THOMAS, Deborah A et al.Cancer. 2012, Vol 118, Num 3, pp 848-855, issn 0008-543X, 8 p.Article

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in MyelofibrosisPARDANANI, Animesh; GOTLIB, Jason R; JAMIESON, Catriona et al.Journal of clinical oncology. 2011, Vol 29, Num 7, pp 789-796, issn 0732-183X, 8 p.Article